Generic drug makers invited to trial international approval pathway

Generic drug makers are being invited to participate in an international pilot program that could enable them to obtain authorization to market their products at roughly the same time in the EU and in one or more of the following countries: Australia, Canada, Taiwan or Switzerland1.